Enhertu plus Perjeta showed significant improvement in progression-free survival in HER2-positive metastatic breast cancer patients compared to standard treatment. The DESTINY-Breast09 trial is the ...

Trodelvy plus Keytruda significantly improves progression-free survival in metastatic triple-negative breast cancer expressing PD-L1 compared to Keytruda and chemotherapy. The safety profile of the ...

CI Games has released Lords of the Fallen Version 2.0, a huge update to the game that brings improvements to combat, characters, adds shared progression in co-op, and also introduces a free Friend ...

No major progression or sonic traverse, and a lot of stewing in a shallow garage pool where parameters become all too clear all too quickly. Just when a groove or hypnotic bass line starts to massage ...

Chief among the biggest additions is the addition of Shared-Progression Cross-Play Cooperative Play, as well as the Free Friend’s Pass, the latter allowing you to invite someone who doesn’t ...

We're talking big, big stuff here - shared-progression crossplay co-op, a free Friend's Pass for whoever you want to play online with, upgrades to combat and movement, a massively improved character ...

However, the mechanistic role of PCNA in HCC progression remains poorly understood. This study aimed to investigate how PCNA regulates DNA damage repair and cell cycle progression in HCC, with a focus ...

The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease. Lecanemab is indicated ...

7,11,12 “Today’s decision makes lecanemab the first treatment option in the European Union that can slow the progression of early Alzheimer’s disease and is a key step to making the medicine available ...

Bungie has confirmed that Marathon will support cross-progression across PC via Steam, PlayStation 5, and Xbox Series X|S consoles. This feature was announced alongside crossplay back in 2023 and ...

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.